Optimizing Lumipulse plasma pTau217/Aβ42 ratio cutpoints in an Asian cohort with high cerebrovascular disease burden

The generalizability of FDA-cleared Lumipulse plasma pTau217 / A{beta}42 ratio cutpoints to Asian populations remains uncertain, especially in those with high burden of concomitant cerebrovascular disease (CeVD). We evaluated pTau217, A{beta}42 and their ratio in 205 Singapore-based participants with corresponding amyloid neuroimaging. In-house cutpoints were derived using a three-range strategy targeting 95% sensitivity and specificity. Plasma pTau217/A{beta}42 ratio outperformed pTau217 alone (area under the curve, 0.951 versus 0.925; p=0.004), with comparable performance across CeVD severit

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.